Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage.

doi:10.1016/j.antiviral.2015.01.014

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage.

Antiviral research - 1 Apr 2015

Boglione Lucio, Cusato Jessica, Cariti Giuseppe, Di Perri Giovanni, D'Avolio Antonio

Abstract excerpt

The treatment of patients with HCV genotype 1 is quickly changing. The clinician could optimize the selection of patients who may benefit from standard therapy with pegylated-interferon and ribavirin instead of more expensive new combinations with the directly acting antivirals. We retrospectively examined in our cohort of 232 patients with genotype 1 infection the role of interleukin 28B (both rs8099917 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Interferons

Share to Interleukins

Share to Liver Cirrhosis

Share to Polyethylene Glycols

Share to Ribavirin

Source

Open in PubMed

Identifiers

PMID: 25660111
DOI: 10.1016/j.antiviral.2015.01.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage.PMID 25660111Read ↗

Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.Semantic proximity Read ↗

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.Semantic proximity Read ↗

The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.Semantic proximity Read ↗

High predictability of a sustained virological response (87%) in chronic hepatitis C virus genotype 1 infection treatment by combined IL28B genotype analysis and γ-glutamyltransferase/alanine aminotransferase ratio: a retrospective single-center study.Semantic proximity Read ↗

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.Semantic proximity Read ↗

Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.Semantic proximity Read ↗

Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients.Semantic proximity Read ↗

Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.Semantic proximity Read ↗

Genomics and HCV infection: progression of fibrosis and treatment response.Semantic proximity Read ↗

IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma.Semantic proximity Read ↗

Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients.Semantic proximity Read ↗

Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.